PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 220.00
Bid: 218.50
Ask: 219.50
Change: -2.00 (-0.90%)
Spread: 1.00 (0.458%)
Open: 218.50
High: 224.50
Low: 217.00
Prev. Close: 222.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS: Micro Focus chair and new CFO buy shares

Mon, 20th Dec 2021 16:20

(Alliance News) - The following is a round-up of share dealings by London-listed company directors and managers announced on Monday and not separately reported by Alliance News:

----------

Micro Focus International PLC - Newbury, Berkshire-based enterprise software firm - Chair Greg Lock buys 300,000 shares at 348.10 pence, worth GBP1.0 million, on Friday last week. Lock and his wife now have 835,000 shares in total. Chief Financial Officer Matthew Ashley and wife Charlotte buy 43,280 shares in total at 346.58p, worth GBP150,000, also on Friday. The purchase is their only holding. Ashley joined Micro Focus in late June from bookmaker William Hill.

----------

Bank of Georgia Group PLC - Tbilisi, Georgia-based lender - Non-Executive Director Alasdair Breach buys 75,671 shares via Gemsstock Ltd at GBP15.54 and GBP15.56 each, worth GBP1.2 million, on Thursday last week. Breach has bought more than GBP6 million in Bank of Georgia shares since the end of November.

----------

Chaarat Gold Holdings Ltd - gold miner in Armenia and mine developer in Kyrgyz Republic - Chair Martin Andersson buys 5.5 million shares via Labro Investments Ltd at 19.00p, worth GBP1.1 million, on Thursday and Friday. Andersson now is interested in 310.9 million shares directly and via Labro, a 45.1% stake. He also is interested in a 2.9% stake via financial instruments, meaning his total voting rights are 48.0%.

----------

Anglo Pacific Group PLC - natural resources royalty and streaming - Chief Executive Officer Julian Treger sells 650,000 shares via Kings Chapel International Ltd at average 129.19p, worth GBP839,735, on Monday through Friday last week. Treger retains 3.1 million shares, a 1.8% stake. Non-Executive Chair Patrick Meier buys 100,775 shares at 129.00p, worth GBP130,000, on Friday. He now has 437,006 shares.

----------

Impax Asset Management Group PLC - London-based investor focused on transition to environmentally sustainable economy - Chief Executive Ian Simm and Chief Financial Officer Charlie Ridge each sell 20,000 shares at 1,339p, together worth GBP535,960, on Friday. Impax says the disposals were partly to pay tax liabilities arising from the vesting of share awards.

----------

Synthomer PLC - Essex-based chemicals - Non-Executive Director Alexander Catto buys 35,000 shares at GBP3.86, worth GBP135,007, on Monday.

----------

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics - Chief of Business & Strategy Bharatt Chowrira buys 25,000 shares at GBP2.90, worth GBP72,500, on Friday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
7 Oct 2022 07:10

Puretech Health confirms possible tie-up with Nektar Therapeutics

(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.

Read more
7 Oct 2022 07:10

Puretech Health confirms possible tie-up with Nektar Therapeutics

(Sharecast News) - PureTech Health said on Friday that it has exchanged indicative, non-binding proposals with US biopharmaceutical company Nektar Therapeutics regarding a possible combination.

Read more
5 Sep 2022 11:40

IN BRIEF: PureTech Health data on fibrosis drug candidate positive

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Posts positive data from a phase 1 trial of its idiopathic pulmonary fibrosis drug candidate LYT-100, or deupirfenidone.

Read more
31 Aug 2022 20:31

TOP NEWS: ConvaTec to join FTSE 100 as abrdn vacates spot

(Alliance News) - FTSE Russell confirmed on Wednesday that the following changes will take effect to its UK indices from the market open on Monday, September 19 after completing its quarterly review.

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 11:03

SMALL-CAP WINNERS & LOSERS: Hunting surges as loss narrows, ups payout

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Thursday.

Read more
25 Aug 2022 10:10

IN BRIEF: PureTech Health loss narrows in "exceedingly strong" half

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Pretax loss in the first half 2022 narrows to USD56.0 million from USD94.9 million a year before. This is due to a USD28.4 million gain on the dilution of its equity interest in Gelesis Inc. Revenue grows 21% to USD7.0 million from USD5.8 million. Attributes this to increased grant revenue from the Vedanta CARB-X and BARDA grant, as well as Alivio and PureTech LYT Inc.

Read more
25 Aug 2022 09:25

PureTech first-half mixed as it makes good clinical progress

(Sharecast News) - PureTech Health reported total first-half revenue of $7.03m on Thursday, up from $5.84m year-on-year.

Read more
24 Aug 2022 17:58

IN BRIEF: PureTech Health's Sonde Health signs deal for COPD in India

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says its founded entity, Sonde Health, has signed a multi-year agreement with specialty pharmaceutical company Koye Pharmaceuticals Pvt Ltd. The agreement is to develop a new vocal biomarker detection and monitoring capability for chronic obstructive pulmonary disease in India. This is Sonde's first partnership with a pharmaceutical firm, PureTech adds.

Read more
23 Aug 2022 18:14

TOP NEWS: abrdn indicated to drop out of FTSE 100, F&C to join

(Alliance News) - Almost 18 months after announcing a name change, abrdn PLC's blue-chip status is under threat, according to indicative index changes provided by FTSE Russell on Tuesday.

Read more
22 Aug 2022 09:15

PureTech Health's Akili raises USD163 million via Nasdaq IPO

(Alliance News) - PureTech Health PLC said founded entity Akili Inc will start trading on the Nasdaq Capital Market on Monday, after raising funds which will go towards video-game based treatment for children.

Read more
9 Aug 2022 09:31

PureTech gets USD115 million from sale of Karuna Therapeutics shares

(Alliance News) - PureTech Health PLC on Tuesday announced it received USD115.4 million after selling a portion of its stake in Karuna Therapeutics Inc.

Read more
8 Aug 2022 17:06

LONDON MARKET CLOSE: Strong start to week as US inflation data looms

(Alliance News) - Stocks in London sprang into the new week after Friday's US jobs data lessened recession fears.

Read more
8 Aug 2022 16:21

IN BRIEF: PureTech shares jump on Karuna Therapeutics trial results

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Says founded entity Karuna Therapeutics reports positive phase III trial results from Emergent-2 trial for KarXT in schizophrenia. KarXT, or xanomeline-trospium, met its primary endpoint in the trial, showing a significant 9.6 point reduction in Positive and Negative Syndrome Scale total score compared to a placebo. The PANSS scale measures the symptom severity of patients with schizophrenia. The trial also met key secondary endpoints, the firm says. Karuna plans to submit a new drug application with the US Food & Drug Administration in mid-2023.

Read more
1 Aug 2022 21:21

IN BRIEF: PureTech Health's Aliki starts phase three study for SDT-001

PureTech Health PLC - Boston, Massachusetts-based clinical-stage biotherapeutics firm - Notes that founded entity Akili Interactive Labs Inc has start a pivotal phase three randomised, controlled study of SDT-001, a candidate designed to improve the measures of attention in children diagnosed with ADHD.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.